-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Celltrion, a pharmaceutical company, recently published the interim results of a Phase I clinical trial of CT-P59 (a drug candidate against COVID-19 monoclonal antibodies), which showed that CT-P59 has good safety, toerability and pharmacodynamics.
phase I clinical trial was a randomized, double-blind and placebo-controlled trial designed to assess the safety, toerability and pharmacodynamics of CT-P59 in healthy subjects.
results showed that there were no significant drug-related adverse events (AE) and no adverse events occurred in the maximum to-dosage group. "In addition to these encouraging safety results, we launched commercial production of CT-P59 this month to ensure that if the trials are successful, we can meet the urgent needs of the global fight against virus therapy," said Dr. Sang Jon Lee, Senior Executive Vice President,
Celltrion.
Celltrion has launched a global Phase I clinical trial of CT-P59 in patients with mild COVID-19 and plans to conduct further Phase II and PHASE III trials in 12 countries, including South Korea.
CT-P59 has been identified as a potential treatment for COVID-19.
in preclinical data, the drug candidate was able to reduce the load of sars-CoV-2 virus by 100 times and reduce inflammation of the lungs.
.